Argos Therapeutics, Inc. (ARGS) Downgraded by Zacks Investment Research to “Sell”
Zacks Investment Research downgraded shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) from a hold rating to a sell rating in a research report sent to investors on Monday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
Separately, FBR & Co reduced their price objective on shares of Argos Therapeutics from $2.00 to $1.20 and set a mkt perform rating for the company in a research report on Wednesday, April 19th. One research analyst has rated the stock with a sell rating and three have issued a hold rating to the company’s stock. Argos Therapeutics has a consensus rating of Hold and an average target price of $3.23.
Shares of Argos Therapeutics (ARGS) traded down 7.035% during midday trading on Monday, reaching $0.222. 1,524,566 shares of the company traded hands. The company has a 50-day moving average of $0.30 and a 200 day moving average of $1.04. The firm’s market capitalization is $9.18 million. Argos Therapeutics has a 12-month low of $0.22 and a 12-month high of $5.68.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,442.99%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.10 million. On average, equities analysts forecast that Argos Therapeutics will post ($1.14) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/15/argos-therapeutics-inc-args-downgraded-by-zacks-investment-research-to-sell.html.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.